Bind announced a $105 million Series B funding round, as investors show continued confidence in the Bind approach to health insurance innovation and market interest.
Bind believes people deserve to see treatment options and compare costs in advance of care, so they can make informed choices that meet their personal needs and conditions. With its entirely new model of health insurance design, Bind gives people something they’ve never experienced with health insurance —cost certainty and coverage flexibility without the barrier of a deductible or coinsurance.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
“To break the cost curve for both employers and employees, we went all-in on building a health plan that provides the tools needed to see cost and quality comparisons, as well as treatment path options across conditions. And we removed unnecessary affordability barriers, like deductibles and coinsurance,” said Bind CEO Tony Miller. “Bind has proven when people have cost clarity, they buy more effective and efficient care—and that makes health care more affordable for everyone.”
The proceeds from this round will be used to rapidly accelerate the company’s growth and expansion associated with its recent announcement that Bind’s personalized health plan will be offered on a fully-insured basis to employers with more than 50 employees, launching immediately in the state of Florida. Bind expects to serve more than 30 states with its fully-insured offering by year-end 2021.
Click here to read more.
ChromaCode announced that since receiving FDA EUA in June, the company has shipped one million units of its HDPCR SARS-CoV-2 assay.
Be Biopharma seeks to engineer B cells, a type of white blood cell, as a new approach to cell therapy. It has launched with a $52 million Series A round. Atlas Venture and RA Capital Management led the round with participation from Alta Partners, Longwood Fund and Takeda Ventures Inc.
“B cells play a key role in combatting diseases by catalyzing humoral immunity – the arm of the immune system that manufactures large quantities of proteins to neutralize disease-causing pathogens and manipulate immune cell behavior,” said Be Biopharma co-founder David Rawlings, MD, Director, Center for Immunity and Immunotherapies, Seattle Children’s Research Institute and Professor of Pediatrics, University of Washington School of Medicine.
Click here to read more.
MedCity’s INVEST Precision Medicine Virtual conference will showcase startups across health IT and life sciences. If you’re a startup, click here to submit an application to present your company.
Picture: akindo, Getty Images
